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abstract: Preterm birth remains the leading cause of neonatal mortality and morbidity worldwide. There are currently few effective ther-
apies and therefore an urgent need for novel treatments. Although there is much focus on trying to alter gestation of delivery, the primary aim of
pretermbirthprevention therapies shouldbe to reduceprematurity relatedmortality andmorbidity.Given the link between intrauterine infection
and inﬂammation and preterm labour (PTL), we hypothesized that administration of lipoxins, key anti-inﬂammatory and pro-resolution media-
tors, could be a useful novel treatment for PTL. Using a mousemodel of infection-induced PTL, we investigatedwhether 15-epi-lipoxin A4 could
delay lipopolysaccharide (LPS)-induced PTL and reduce pup mortality. On D17 of gestation mice (n ¼ 9–12) were pretreated with vehicle or
15-epi-lipoxin A4 prior to intrauterine administration of LPS or PBS. Although pretreatment with 15-epi-lipoxin A4 did not delay LPS-induced
PTL, there was a signiﬁcant reduction in the mortality amongst prematurely delivered pups (deﬁned as delivery within 36 h of surgery) in mice
treated with 15-epi-lipoxin A4 prior to LPS treatment, compared with those receiving LPS alone (P, 0.05). Quantitative real-time (QRT)-
PCR analysis of utero-placental tissues harvested 6 h post-treatment demonstrated that 15-epi-lipoxin A4 treatment increased Ptgs2 expression
in the uterus, placenta and fetal membranes (P, 0.05) and decreased 15-Hpgd expression (P, 0.05) in the placenta and uterus, suggesting that
15-epi-lipoxin A4 may regulate the local production and activity of prostaglandins. These data suggest that augmenting lipoxin levels could be a
useful novel therapeutic option in the treatment of PTL, protecting the fetus from the adverse effects of infection-induced preterm birth.
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Introduction
Preterm labour (PTL), deﬁned as labour before 37 weeks gestation,
remains a major obstetric problem estimated to affect between 5 and
18% of pregnancies worldwide, with 15 million babies born prema-
turely each year (March of Dimes, 2012). Despite advances in the
medical care of preterm infants, there are currently few effective treat-
ment options and premature birth remains the leading cause of neonatal
mortality. Indeed, preterm birth is estimated to account for up to 75%of
neonatal deaths (Goldenberg et al., 2008). Additionally, preterm birth is
associatedwith an increased riskof a rangeof short-termmorbidities and
long-term disabilities, including cerebral palsy, bronchopulmonary dys-
plasia (BPD), retinopathy of prematurity and learning difﬁculties (Saigal
and Doyle, 2008).
Spontaneous labour at term is now considered to be an inﬂammatory
event that is associated with an immune cell inﬁltration into the cervix,
myometrium and fetal membranes and increased production of
pro-inﬂammatory mediators in the utero-placental tissues (Denison
et al., 1998; Thomson et al., 1999; Sennstrom et al., 2000; Young et al.,
2002; Osman et al., 2003). Although the causes of PTL are often
unclear, many cases are associated with the presence of occult or
overt intrauterine infection (Goldenberg et al., 2000) and the premature
activation of these inﬂammatory pathways is likely responsible for PTL in
this scenario. Animal models have conﬁrmed a causal link between intra-
uterine infection and inﬂammation and PTL, given that injection of bac-
terial components, such as LPS or pro-inﬂammatory cytokines, such as
tumour necrosis factor-a (TNF-a) or interleukin (IL)-1b reliably
induce PTL (Romero et al., 1991; Elovitz et al., 2003; Sadowsky et al.,
2006).Ourown in vitro studies have shown that LPS directly induces con-
tractions of isolated human myometrial cells (Hutchinson et al., 2013).
Inﬂux of immune cells likely also contributes to the process, although
further work is required to deﬁne their precise roles (Timmons and
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Mahendroo, 2006; Murphy et al., 2009; Thaxton et al., 2009; Gonzalez
et al., 2011; Rinaldi et al., 2014).
Given the link between inﬂammation and spontaneous labour onset,
and the association between intrauterine infection and PTL, there has
been a growing interest in examining whether anti-inﬂammatory agents
could be effective novel therapeutic options for PTL (Rinaldi et al.,
2011). Animal studies have been invaluable in demonstrating the poten-
tial of anumberof anti-inﬂammatoryagents todelaypretermdeliveryand
improvepup survival, including IL-10 (Terrone et al., 2001; Rodts-Palenik
et al., 2004; Robertson et al., 2006), TLR-4 signalling blockade (Adams
Waldorf et al., 2008; Li et al., 2010), NFkB inhibitors (Nath et al.,
2010; Chang et al., 2011) and 15-deoxy-D12,14-prostaglandin J2
(15d-PGJ2) (Pirianov et al., 2009).
The understanding that the resolution of inﬂammation is an active
process involving the production of mediators with speciﬁc anti-
inﬂammatory and pro-resolution actions has provided new pathways to
target in the search for novel treatments for inﬂammation-associated
pathologies (Gilroy et al., 2004; Serhan et al., 2008). The arachidonic acid-
derived lipid mediators, lipoxins, were the ﬁrst family of mediators recog-
nized to have dual-acting anti-inﬂammatory and pro-resolution actions
(Serhan et al., 1984; Ryan and Godson, 2010). During the resolution
phase of an inﬂammatory response, in addition to the native lipoxins
(lipoxin A4 and lipoxin B4), arachidonic acid can, in the presence of
aspirin, also be converted to aspirin-triggered or 15-epi-lipoxins (15-
epi-lipoxin A4 and 15-epi-lipoxin B4) (Chiang et al., 2005). The anti-
inﬂammatory and pro-resolution actions of lipoxins and 15-epi-lipoxins
include: inhibiting neutrophil activation, adhesion and chemotaxis
(Papayianni et al., 1996; Filep et al., 2005; Maderna and Godson, 2009);
counteracting neutrophil anti-apoptotic signals (El Kebir et al., 2007,
2009); triggering non-phlogistic phagocytosis of apoptotic neutrophils
by macrophages (Godson et al., 2000); stimulating monocyte adhesion
and migration (Maddox and Serhan, 1996); and down-regulating pro-
inﬂammatory cytokine production (Wu et al., 2008; Kure et al., 2009).
The therapeutic potential of lipoxins has been widely demonstrated in
animalmodelsof a rangeof inﬂammation-associatedpathologies, including
asthma (Levy et al., 2002) and lung injury (El Kebir et al., 2009), arthritis
(Zhang et al., 2008; Conte et al., 2010) and inﬂammatory bowel diseases
(Gewirtz et al., 2002). Within the reproductive tract, studies have identi-
ﬁed a role for lipoxin signalling in endometriosis (Chen et al., 2010; Xu
et al., 2012), embryo implantation (Xiong et al., 2013) and spontaneous
miscarriage (Xu et al., 2013). To date, the role of lipoxins in regulating in-
ﬂammation in parturition has been less well explored (Hutchinson et al.,
2011). However, using an in vitro model, we previously showed that ex-
pression of the lipoxin receptor, FPR2/ALX, is increased in myometrial
tissue obtained from women during term labour (compared with tissue
obtained from non-labouring women); and that lipoxin treatment down-
regulated LPS-induced inﬂammatory gene expression in myometrial
explant culture (Maldonado-Perez et al., 2010).
Given evidence that lipoxins could be involved in regulating the inﬂam-
mation associated with labour, and the therapeutic potential of lipoxin
administration demonstrated in animal models of other inﬂammation-
associated pathologies, we hypothesized that lipoxins could be effective
therapeutic agents for the treatment of infection-induced PTL. In the
study described here, using amousemodel of LPS-induced PTL,weeval-
uated the effect of pretreatment with 15-epi-lipoxin A4 on LPS-induced
preterm delivery, pup mortality and the LPS-induced inﬂammatory re-
sponse of the utero-placental tissues.
Materials andMethods
Mouse model of infection-induced PTL
All animal studies were conducted under a UK Home Ofﬁce licence to JEN
(60/4241) and were approved by the University’s ethical board and the
UK Home Ofﬁce. Timed-pregnant CD-1 mice were obtained from
Charles River Laboratories (Margate, UK) on D9-11 of gestation (the day
vaginal plug was found was designated D1 of gestation). Mice were acclima-
tized for a minimum of 6 days prior to surgery. On D17 of gestation, a
mini-laparotomy procedure was performed to expose the uterine horns,
as previously described (Rinaldi et al., 2014). The number of viable pups in
each horn was recorded prior to injection. In LPS dose–response experi-
ments, the horn with the greater number of fetuses was injected with
either LPS (5–20 mg; from Escherichia coli 0111:B4; Sigma-Aldrich, Poole,
UK) or sterile PBS (Gibco, Life Technologies Ltd, Paisley, UK) each in a
25 ml volume using a 33-gauge Hamilton syringe. Injections were performed
directly into the uterine cavity between the ﬁrst and second anterior fetuses.
Care was taken not to enter any amniotic sacs. The wound was then closed
and mice received a subcutaneous injection of Vetergesic analgesia (Alstoe
Ltd, York, UK) at a dose of 0.03 mg/ml in 60 ml.
Mice were kept at 308C while they recovered from surgery, before being
transferred to individual cages for continuous monitoring using individual
CCTV cameras and a digital video recorder. The time to delivery was
recorded and deﬁned as the number of hours from the time of intrauterine
injection, to delivery of the ﬁrst pup. Pretermdeliverywas deﬁned as delivery
of the ﬁrst pup within 36 h of intrauterine injection. Term delivery in CD1
mice occurs on D19-21 of gestation, and we previously reported that
mean (+SEM) time to delivery in a ‘no surgery’ control group of CD1
mice was 51.34+1.13 h (n ¼ 8), with all these mice delivering on D19 of
gestation (Rinaldi et al., 2014). Based on these data, delivery within 36 h of
injection was chosen as preterm in our model. Within 12–24 h of delivery,
the number of live/dead pups was recorded and the mortality rate per
dam was calculated by dividing the number of dead pups by the number of
viable pups counted in utero at the time of intrauterine injection.
In experiments to determine whether lipoxin administration could modu-
late LPS-induced preterm delivery and pup mortality, mice were pretreated
with 15-epi-lipoxin A4 prior to intrauterine PBS or LPS administration. The
15-epi-lipoxin A4 analogue was chosen as several studies have reported
that it is more stable, has a longer half-life in vivo and has more potent anti-
inﬂammatory and pro-resolution effects, compared with lipoxin A4 (Serhan
et al., 1995; Serhan, 1997; Gewirtz et al., 1998). Mice received an intra-
peritoneal (i.p.) injection of vehicle (PBS + 1% ethanol) or 15-epi-lipoxin
A4 (doses of 12.5 or 125 ng in a volume of 100 ml; Cayman Chemical, Ann
Arbor, MI, USA), 1–2 h prior to intrauterine administration of PBS or 20 mg
LPS. Therefore, there were ﬁve treatment groups: vehicle (i.p. injection of
vehicle, followed by intrauterine PBS); 125 ng 15-epi-lipoxin A4 (i.p. injection
of 125 ng 15-epi-lipoxin A4 followed by intrauterine PBS); LPS (i.p. injection
of vehicle followed by intrauterine LPS); 12.5 ng 15-epi-lipoxin A4 + LPS
(i.p. injection of 12.5 ng 15-epi-lipoxin A4 followed by intrauterine LPS) and
125 ng 15-epi-lipoxin A4 + LPS (i.p. injection of 125 ng 15-epi-lipoxin A4 fol-
lowed by intrauterine LPS). The time to delivery and pup mortality rate was
then recorded in each treatment group, as described earlier.
Tissue collection
In a separate cohort of mice, to examine the effect of pretreatment with
15-epi-lipoxin A4 on the LPS-induced inﬂammatory response of the utero-
placental tissues, tissues were collected 6 h post-surgery from mice
treated with either vehicle or 15-epi-lipoxin A4 (0.25 and 2.5 mg) 1–2 h
prior to intrauterine administration of PBS or 20 mg LPS. Higher doses of
15-epi-lipoxinA4wereused in these6 h experiments tomaximize thepoten-
tial anti-inﬂammatory actions of 15-epi-lipoxin A4. All doses of 15-epi-lipoxin
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A4used in this studywere chosen basedonpublished literature,which shows
that lipoxins can be tolerated and have strong anti-inﬂammatory and pro-
resolution effects over a wide range of doses in vivo (Levy et al., 2002; El
Kebir et al., 2009; Kure et al., 2009; Conte et al., 2010; Borgeson et al.,
2011; Zhou et al., 2011). Mice were culled by lethal exposure to CO2 and
all pups were removed from the uterine horns and decapitated. Uterine
tissuewas sampled from three ﬁxed sites within the uterus; fetal membranes
were dissected free from the placenta, and these tissues were collected
from three separate gestational sacs. Tissues were stored in RNAlaterw
(Sigma-Aldrich) at 2808C until processing.
Quantitative real-time PCR
Total RNAwas extracted from uterus, fetal membranes and placental tissue
collected 6 h post-surgery using the RNeasy mini kit (Qiagen, Crawley, UK)
as per the manufacturer’s guidelines. Total RNA (300 ng) was reverse tran-
scribed using the High Capacity cDNA Reverse Transcription kit (Applied
biosystems, Life Technologies Ltd, Paisely, UK). Quantitative real-time
PCR (qRT-PCR)was carriedout toquantify themRNAexpressionof speciﬁc
genes of interest. Predesigned gene expression assays from Applied Biosys-
tems were used to examine the expression of 15-hydroxy prostaglandin de-
hydrogenase (15-Hpgd) (Mm00515121_m1), Il-10 (Mm00439614_m1),
Il-1b (Mm00434228_m1), Tnf-a (Mm99999068_m1), Cxcl1 (Mm0420
7460_m1), Cxcl2 (Mm00436450_m1) and Cxcl5 (Mm00436451_g1).
Primer and probe sequences for b-actin, Ptgs2 and Il-6 were designed using
Primer Express Software (version 3.0). Details of designed b-actin, Ptgs2
and Il-6 primer and probe sequences are given in Table I. Target gene expres-
sionwas normalized for RNA loading usingb-actin and the expression in each
samplewas calculated relative to a calibrator sample (untreatedD18 uterus),
which was included in all reactions, using the 22DDCt method of analysis.
All qRT-PCR analysis was performed on an Applied Biosystems 7900HT
instrument.
Statistical analysis
Data are presented as mean+ SEM.Where data were not normally distrib-
uted they were transformed prior to analysis to achieve normal distribution.
Time to delivery data was log-transformed before analysis; and the propor-
tion of dead pups was arc-sin transformed prior to analysis. Data were ana-
lysedbyone-wayanalysis of variance to compare treatment groups, followed
by either Dunnett’s or Newman–Keuls multiple comparison tests between
treatment groups to identify signiﬁcant differences. All statistical analyses
were performed using GraphPad Prism 5.0 software (Graph Pad, San
Diego,CA,USA). P, 0.05was considered to indicate statistical signiﬁcance.
Results
Intrauterine LPS administration
dose-dependently increases pup mortality
As we have previously reported, intrauterine LPS administration dose-
dependently induces PTL in a mouse model (Rinaldi et al., 2014). To
assess the effects of intrauterine LPS treatment on pup mortality mice
were treated with increasing doses of LPS and the pup mortality rate
was calculated following delivery. Pup mortality was increased in re-
sponse to administration of increasing doses of intrauterine LPS, with a
signiﬁcantly higher proportion of dead pups born to mice treated with
20 mg LPS, comparedwith the PBS control group (mean+ SEMpropor-
tion of dead pups 0.75+ 0.05 versus 0.40+0.06, respectively, P,
0.001; Fig. 1A). To further investigate whether this observed increase
in pup mortality in the 20 mg LPS group was simply due to a higher pro-
portion of preterm deliveries in this group, rather than a direct effect of
the LPS treatment, pup mortality was also assessed only in mice deliver-
ing preterm (deﬁned as delivery within 36 h of surgery). Even amongst
mice delivering preterm, fetal mortality was still signiﬁcantly greater in
mice treated with 20 mg LPS group compared with PBS (mean+ SEM
proportion of dead pups 0.85+0.04 versus 0.49+ 0.11, respectively,
P, 0.01; Fig. 1B). Subsequent experiments were performed with
20 mg LPS as this dose has been shown to induce preterm delivery reli-
ably in our model with the least variation (Rinaldi et al., 2014).
Pretreatment with 15-epi-lipoxin A4 reduces
pup mortality without delaying LPS-induced
preterm delivery
To investigate the therapeutic potential of lipoxin to delay pretermdeliv-
ery and reduce prematurity induced fetal mortality, mice were pre-
treated with 15-epi-lipoxin A4 1–2 h prior to intrauterine LPS (20 mg)
or PBS administration. Control mice were pretreated with vehicle
prior to intrauterine LPS or PBS administration. Pretreatment with
125 ng 15-epi-lipoxin A4 prior to intrauterine PBS had no effect on
time to delivery compared with the vehicle control group (Fig. 2A). As
expected mice receiving intrauterine LPS delivered signiﬁcantly earlier
than the vehicle control group (LPS mean time to delivery: 27.54 h+
SEM 6.33; versus vehicle mean time to delivery: 55.40 h+ SEM 6.40;
P, 0.001; Fig. 2A). Pretreatment with either 12.5 or 125 ng 15-epi-
lipoxin A4 prior to intrauterine LPS administration did not delay
LPS-induced PTL. Mice in these groups still delivered signiﬁcantly earlier
than the vehicle control group (mean+ SEM time to delivery 12.5 ng
15-epi-lipoxin A4 + LPS: 27.02+4.57 h; mean time delivery in 125 ng
15-epi-lipoxin A4 + LPS: 26.82+2.61; P, 0.01 versus vehicle).
Again as expected, mice treated with LPS alone had signiﬁcantly
increased pup mortality compared with the vehicle group (mean+
SEM proportion of dead pups: 0.84+ 0.09; P, 0.01; Fig. 2B). Interest-
ingly, pretreatment with 125 ng 15-epi-lipoxin A4 prior to intrauterine
PBS signiﬁcantly reduced pup mortality, compared with the vehicle
control group (mean+ SEM proportion of dead pups 0.13+0.05
versus 0.42+0.1, respectively, P, 0.05; Fig. 2B).Within the subgroup
of mice delivering preterm (within 36 h of surgery), pretreatment with
125 ng 15-epi-lipoxin A4 prior to intrauterine LPS signiﬁcantly reduced
pup mortality, compared with mice receiving LPS alone (mean
proportion+ SEM of dead pups 0.55+0.12 versus 0.97+0.02, re-
spectively; P, 0.05; Fig. 2C).
........................................................................................
Table I Primer and probe sequences designed using
Primer Express software.
Gene Primer/Probe Sequence
b-actin Forward 5′-GCTTCTTTGCAGCTCCTTCGT-3′
Reverse 5′-GCGCAGCGATATCGTCATC-3′
Probe 5′-CACCCGCCACCAGTTCGCCAT-3′
Ptgs2 Forward 5′-GCTTCGGGAGCACAACAG-3′
Reverse 5′-TGGTTTGGAATAGTTGCTC-3′
Probe 5′-TGTGCGACATACTCAAGCA-3′
Il-6 Forward 5′-CCACGGCCTTCCCTACTTC-3′
Reverse 5′-TGCACAACTCTTTTCTCATTCCA-3′
Probe 5′-TCACAGAGGATACCACTCCCAA
CAGACCTG-3′
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Pretreatmentwith 15-epi-lipoxinA4 alters the
expression of Ptgs2 and 15-Hpgd in the
utero-placental tissues, but does not
attenuate LPS-induced expression of classical
pro-inﬂammatory markers
To examine whether pretreatment with 15-epi-lipoxin A4 affected the
LPS-induced inﬂammatory response of the utero-placental tissues,
qRT-PCR analysis was performed on uterus, placenta and fetal mem-
branes collected 6 h post-surgery. The mRNA expression of several
key inﬂammatory genes associated with parturition was quantiﬁed.
The genesmeasuredwere: two of the key enzymes responsible for regu-
lating prostaglandin synthesis and breakdown, respectively, Ptgs2 and
15-Hpgd; the pro-inﬂammatory cytokines Il-1b, Tnf-a and Il-6; and the
chemokines Cxcl1, Cxcl2 and Cxcl5. To investigate the anti-inﬂammatory
actions of 15-epi-lipoxin A4, we administered higher doses (0.25 and
2.5 mg) of 15-epi-lipoxin A4 1–2 h prior to LPS or vehicle to try tomaxi-
mize the anti-inﬂammatory effects in these 6 h experiments. As stated
earlier, all dosesof 15-epi-lipoxinA4usedwerewithin the rangeof effect-
ive doses used in vivo in previously published studies.
In theuterus,Ptgs2expressionwas signiﬁcantlyelevated in response to
2.5 mg 15-epi-lipoxin A4 alone (P, 0.01), LPS alone (P, 0.01), and
0.25 mg and 2.5 mg 15-epi-lipoxin A4 + LPS (P, 0.001; Fig. 3A), com-
pared with the vehicle control group. Co-treatment with 2.5 mg
15-epi-lipoxin A4 and LPS also signiﬁcantly increased uterine Ptgs2 ex-
pression compared with treatment with LPS alone (P, 0.05; Fig. 3A).
Conversely, uterine 15-Hpgd expression was signiﬁcantly reduced in
mice treated with 2.5 mg 15-epi-lipoxin A4 prior to intrauterine PBS,
compared with vehicle (P, 0.01) and LPS alone (P, 0.05). LPS alone
did not signiﬁcantly alter 15-Hpgd expression; however, mice treated
with 0.25 mg 15-epi-lipoxin A4 + LPS and 2.5 mg 15-epi-lipoxin A4 +
LPS had signiﬁcantly reduced uterine 15-Hpgd expression, compared
with the vehicle group (P, 0.001). Additionally pretreatment with
0.25 mg 15-epi-lipoxin A4 and 2.5 mg 15-epi-lipoxin A4 prior to intra-
uterine LPS, signiﬁcantly reduced uterine expression of 15-Hpgd, com-
pared with LPS alone (P, 0.001; Fig. 3A).
Placental Ptgs2 expression was signiﬁcantly elevated in mice treated
with 2.5 mg 15-epi-lipoxin A4 prior to intrauterine PBS, compared with
vehicle (P, 0.05; Fig. 3B) and LPS alone (P, 0.05). Ptgs2 expression
in the placenta was unaffected by LPS alone, but pretreatment with
15-epi-lipoxin A4 at both 0.25 and 2.5 mg prior to intrauterine LPS ad-
ministration signiﬁcantly increased Ptgs2 expression compared with
both the vehicle control group (P, 0.01 and P, 0.001, respectively;
Fig. 3B) andcomparedwithLPS treatment alone (P, 0.001; Fig. 3B). Pla-
cental 15-Hpgd expression was signiﬁcantly down-regulated in response
to 2.5 mg 15-epi-lipoxin A4 alone (P, 0.001), LPS alone (P, 0.05),
0.25 mg 15-epi-lipoxin A4 + LPS (P, 0.01) and 2.5 mg 15-epi-lipoxin
A4 + LPS (P, 0.05; Fig. 3B), compared with the vehicle control group.
In the fetal membranes, intrauterine LPS treatment alone did not sig-
niﬁcantly alter Ptgs2 expression; however, mice treated with 0.25 mg
15-epi-lipoxinA4 + LPS had signiﬁcantly elevated Ptgs2 expression com-
pared with the vehicle control group (P, 0.05; Fig. 3C); and mice
treated with 2.5 mg 15-epi-lipoxin A4 + LPS had signiﬁcantly elevated
Cox-2 expression, compared with both the vehicle control group and
LPS alone (P, 0.05; Fig. 3C). Expression of 15-Hpgd in the fetal mem-
branes was signiﬁcantly reduced in response to LPS treatment alone
(P, 0.01), 0.25 mg 15-epi-lipoxin A4 + LPS (P, 0.01) and 2.5 mg
15-epi-lipoxin A4 + LPS (P, 0.001; Fig. 3B).
In contrast to the effects on Ptgs2 and 15-Hpgd, pretreatment with
15-epi-lipoxin A4 at either 0.25 or 2.5 mg prior to intrauterine LPS did
not attenuateoramplify theLPS-inducedexpressionof the classical inﬂam-
matory markers Tnf-a and Il-1b in the uterus (Fig. 4A), placenta (Fig. 4B)
and fetal membranes (Fig. 4C). Similarly, pretreatmentwith 15-epi-lipoxin
A4 did not alter the LPS-induced expression of the other inﬂammatory
mediators examined, Il-6, Cxcl1, Cxcl2 and Cxcl5 (data not shown).
Pretreatment with 15-epi-lipoxin A4 does not
further up-regulate the LPS-induced
expression of Il-10 in the utero-placental
tissues
Previous studies have reported that one mechanism by which lipoxins
exert anti-inﬂammatory actions is by up-regulating the expression of
Figure1 Effect of intrauterine LPS administrationonpupmortality.Theproportionof deadpupsweredetermined inmice receiving intrauterine injection
of either phosphate-buffered saline (PBS; n ¼ 35), 5 mg LPS (n ¼ 6), 10 mg LPS (n ¼ 11), 15 mg LPS (n ¼ 8) and20 mg LPS (n ¼ 42). (A) Proportionof dead
pups in all litters. (B) Proportion of dead pups in premature litters (delivered within 36 h of surgery); [PBS (n ¼ 14), 5 mg LPS (n ¼ 3), 10 mg LPS (n ¼ 6),
15 mg LPS (n ¼ 6) and 20 mg LPS (n ¼ 35)]. Data presented as mean+ SEM (error bars); **P, 0.01, ***P, 0.001, compared with PBS.
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the anti-inﬂammatory cytokine, IL-10 (Baker et al., 2009; Borgeson et al.,
2011). Therefore, we investigated the mRNA expression of Il-10 in the
utero-placental tissues 6 h post-surgery using qRT-PCR. Treatment
with LPS alone resulted in signiﬁcantly elevated expression of Il-10 in
the uterus (P, 0.05; Fig. 5A), placenta (P, 0.01; Fig. 5B) and fetal
membranes (P, 0.001; Fig. 5C). However, pretreatment with
15-epi-lipoxinA4, at either0.25or2.5 mg, prior to intrauterine LPS treat-
ment did not result in a further increase in Il-10 expression, compared
with LPS alone.
Discussion
We have previously shown the anti-inﬂammatory effects of the
dual-acting anti-inﬂammatory and pro-resolution lipid mediators, lipox-
ins, in human gestational tissues in vitro (Maldonado-Perez et al., 2010).
Here, we tested the efﬁcacy of 15-epi-lipoxin A4 as a novel therapeutic
agent in an in vivo mouse model of infection-induced PTL. Contrary to
our original hypothesis, we did not observe a reduction in preterm deliv-
ery or reduced pro-inﬂammatory signalling in mice treated with
15-epi-lipoxin A4. We did, however, show that 15-epi-lipoxin A4 treat-
ment reduced the mortality of prematurely delivered pups and altered
basal and LPS-induced Ptgs2 and 15-Hpgd expression in the utero-
placental tissues.
We believe that the ﬁnding that 15-epi-lipoxin A4 treatment resulted
in a greater proportionof prematurelydeliveredpups being born alive is a
novel and important discovery. Current treatment options for preterm
birth are largely limited to tocolytic therapies that aim to block myome-
trial contractions and prolong gestation. However, there is little convin-
cing evidence that these treatments actually result in improved neonatal
outcome in the long-term. Given that preterm birth remains the single
Figure 2 Effect of pretreatment with 15-epi-lipoxin A4 on time to delivery and pup mortality. Time to delivery and the proportion of dead pups was
determined in mice pretreated with vehicle (n ¼ 12) or 125 ng 15-epi-lipoxin A4 (n ¼ 9), prior to intrauterine PBS; and in mice pretreated with vehicle
(n ¼ 12), 12.5 ng 15-epi-lipoxin A4 (n ¼ 11) or 125 ng 15-epi-lipoxin A4 (n ¼ 11), prior to intrauterine LPS (20 mg) administration. (A) Time to delivery.
(B) Proportion of dead pups in all litters. (C) Proportion of dead pups in premature litters (delivered within 36 h of surgery); [Vehicle (n ¼ 3), 125 ng
15-epi-lipoxinA4 (n ¼ 2), LPS (n ¼ 10), 12.5 ng 15-epi-lipoxinA4 (n ¼ 7) or 125 ng 15-epi-lipoxinA4 (n ¼ 10)]. The 15-epi-lipoxinA4 groupwas excluded
from statistical analysis of the proportion of prematurely delivered dead pups due to n, 3. Data presented as mean+ SEM (error bars); *P, 0.05,
**P, 0.01, ***P, 0.001, compared with vehicle; #P, 0.05 compared with LPS.
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biggest cause of neonatal mortality andmorbidity worldwide, there is an
urgent requirement for novel therapeutic options which are capable of
achieving the ultimate goal of preterm prevention therapies—reduced
perinatal mortality and morbidity. Interestingly a recent paper has
highlighted the potential of lipoxin treatment to treat the preterm-
related lung disease, BPD (Martin et al., 2014). Using a mouse model
of hyperoxia-induced lung injury Martin et al. (2014) reported that
lipoxin A4 treatment given (post-natally) to neonatal pups reduced the
Figure 3 Effect of pretreatment with 15-epi-lipoxin A4 on mRNA
expression of Ptgs2 and 15-Hpgd in the utero-placental tissues.
Uterus, placenta and fetal membranes were collected 6 h post-surgery
from mice pretreated with vehicle (n ¼ 3) or 2.5 mg 15-epi-lipoxin A4
(n ¼ 4), prior to intrauterine PBS; and in mice pretreated with vehicle
(n ¼ 5), 0.25 mg 15-epi-lipoxin A4 (n ¼ 5) or 2.5 mg 15-epi-lipoxin A4
(n ¼ 5), prior to intrauterine LPS administration.ThemRNAexpression
of Ptgs2 and 15-Hpgdwas quantiﬁed by quantitative real-time PCR. (A)
Uterine expression. (B) Placental expression. (C) Expression in the fetal
membranes. Data presented as mean fold change+ SEM (error bars);
*P, 0.05, **P, 0.01, ***P, 0.001, compared with vehicle;
#P, 0.05, ##P, 0.01, ###P, 0.001, compared with LPS.
Figure4 Effect of pretreatmentwith 15-epi-lipoxin A4 onmRNAex-
pression of Tnf-a and Il-1b in the utero-placental tissues. Uterus, pla-
centa and fetal membranes were collected 6 h post-surgery from
mice pretreated with vehicle (n ¼ 3) or 2.5 mg 15-epi-lipoxin A4
(n ¼ 4), prior to intrauterine PBS; and in mice pretreated with vehicle
(n ¼ 5), 0.25 mg 15-epi-lipoxin A4 (n ¼ 5) or 2.5 mg 15-epi-lipoxin A4
(n ¼ 5), prior to intrauterine LPS administration.ThemRNAexpression
of Tnf-a and Il-1b was quantiﬁed by quantitative real-time PCR. (A)
Uterine expression. (B) Placental expression. (C) Expression in the
fetal membranes. Data presented as mean fold change+ SEM (error
bars); *P, 0.05, **P, 0.01, ***P, 0.001, compared with vehicle.
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morphologic and cellular characteristics of lung injury and improved pup
growth; therefore, supporting the hypothesis that pre- and post-natal
lipoxins could be useful novel therapeutic agents to improve neonatal
outcome.
The pup mortality observed in our model is likely to be a result of the
immaturity of the prematurely delivered pups, which if delivered on Day
17 or 18 of gestation are unlikely to be developmentally competent to
survive, and also the LPS treatment given to themice.Owing to the inva-
sive nature of the model, which we have previously shown results in a
local inﬂammatory response, even in mice treated with PBS (Rinaldi
et al., 2014), some of the control mice do deliver prematurely, and
thereforedoexperience somepupmortality.Wearecurrently exploring
other, less invasive methods, to reduce this preterm delivery in our
control group. Importantly, however, we did observe a signiﬁcant reduc-
tion in pup mortality in mice treated with intrauterine PBS if they were
pretreated with 15-epi-lipoxin A4, suggesting that treatment with
15-epi-lipoxin A4 may be able to protect the fetus from the negative
effects of the local inﬂammatory response induced by the surgery.
The mechanism by which 15-epi-lipoxin A4 reduces perinatal mortal-
ity in our model is currently unclear, although our data implicate prosta-
noid regulation via increased Ptgs2 and decreased 15-Hpgd expression
in the uterus and placenta. This increased expression of Ptgs2 could
Figure5 Effect of pretreatmentwith 15-epi-lipoxinA4onmRNAexpressionof Il-10 in the utero-placental tissues.Uterus, placenta and fetalmembranes
were collected 6 h post-surgery frommice pretreated with vehicle (n ¼ 3) or 2.5 mg 15-epi-lipoxin A4 (n ¼ 4), prior to intrauterine PBS; and in mice pre-
treated with vehicle (n ¼ 5), 0.25 mg 15-epi-lipoxin A4 (n ¼ 5) or 2.5 mg 15-epi-lipoxin A4 (n ¼ 5), prior to intrauterine LPS administration. The mRNA
expression of Il-10was quantiﬁed by quantitative real-time PCR. (A) Uterine expression. (B) Placental expression. (C) Expression in the fetal membranes.
Data presented as mean fold change+ SEM (error bars); *P, 0.05, **P, 0.01, ***P, 0.001, compared with vehicle.
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result in increased production of prostaglandins with anti-inﬂammatory
effects, such as PGE2, PGD2 and 15d-PGJ2, as has been described in
other studies (Gilroy et al., 1999; Hodges et al., 2004; Fukunaga et al.,
2005; Bonnans et al., 2006; Zheng et al., 2011; Font-Nieves et al.,
2012). These prostaglandins may act to resolve the inﬂammatory envir-
onment surrounding the fetus, thus leading to the reduced pupmortality
rate observed inmice treatedwith 15-epi-lipoxinA4. Support for this hy-
pothesis comes from a study that reported that administration of
15d-PGJ2 increased pup survival in a mouse model of LPS-induced PTL
(Pirianov et al., 2009).
Another potential mechanism by which 15-epi-lipoxin A4 could be
acting to reduce pup mortality may be by promoting fetal lung matur-
ation. PGE2 has been implicated in regulating fetal pulmonary surfactant
production both in vitro (Acarregui et al., 1990) and in vivo in a sheep
model of intra-amniotic infection (Westover et al., 2012); suggesting
that the 15-epi-lipoxin A4-induced increase in utero-placental Ptgs2
expression may promote fetal lung maturation via increased local PGE2
production. Additionally, a recent study reported that administration
of a synthetic analogue of 15-epi-lipoxin A4 restored expression of
surfactant protein C in lung tissue in a model of bleomycin-induced pul-
monary ﬁbrosis (Guilherme et al., 2013); supporting the hypothesis that
lipoxin administration can regulate lung surfactant production. Further
work examining the inﬂammatory response at several time points is
required to elucidate the relationship between Ptgs2 and 15-epi-lipoxin
A4 in our model, and to identify whether alterations in prostanoid pro-
duction are involved in the reduced pupmortality observed in this study.
Interestingly, the administration of low-dose aspirin to women during
pregnancy has been associated with reduced perinatal death and other
adverse perinatal outcomes (Bujold et al., 2010; Roberge et al., 2013).
As 15-epi-lipoxins are produced in the presence of aspirin, it is possible
that 15-epi-lipoxin A4 is involved in mediating any beneﬁcial effects of
aspirin treatment.Other studies have shown that low-dose aspirin admin-
istration to healthy volunteers leads to signiﬁcantly elevated plasma levels
of 15-epi-lipoxinA4 (Chiang et al., 2004), therefore, itwould be interesting
to assess whether similar mechanisms are acting during pregnancy.
Another important observation from our work which is worthy
of further investigation is the ﬁnding that elevated levels of Ptgs2 were
also observed in uterus and placental tissue obtained from mice
treated with 15-epi-lipoxin A4 alone, even thoughmice in this treatment
group did not go into PTL. Previous studies have demonstrated a central
role for elevated Ptgs2 expression, and subsequent production of pros-
taglandins such as PGF2a and PGE2 in the onset of parturition in mice
(Sugimoto et al., 1997; Gross et al., 1998, 2000; Tsuboi et al., 2003).
However, mice in the 15-epi-lipoxin A4 group delivered at term,
despite having elevated Ptgs2 expression, again suggesting that treatment
with 15-epi-lipoxin A4 may be triggering an alternative prostanoid
pathway, as has been reported in other systems (Zheng et al., 2011).
Interestingly, 15-epi-lipoxin A4 was unable to attenuate LPS-induced
pro-inﬂammatory signalling in ourmodel, which is in contrast to our pre-
viouswork showing that lipoxin treatment in vitro attenuated IL-6 and IL-8
expression in human myometrial explant culture (Maldonado-Perez
et al., 2010). The reasons for these differences are unclear, but may be
a result of differences in the type and dose of lipoxin used in the two
studies, and also the time-point at which tissues were collected from
our in vivomodel. Perhaps if tissues hadbeen collected at a different time-
point, we may have observed alterations in inﬂammatory signalling.
Whilst it is often difﬁcult to extrapolate between animal models and
the clinical scenario in humans, importantly, our in vitro data suggests
that lipoxin treatment may have a more profound impact on inﬂamma-
tory signalling in human tissues.
This study demonstrates for the ﬁrst time that 15-epi-lipoxin A4
reduces pup mortality in a mouse model of LPS-induced PTL. Although
themechanisms by which 15-epi-lipoxin A4may be acting to protect the
prematurely delivered pups from mortality are not currently clear, we
propose that 15-epi-lipoxin A4 may be stimulating the resolution of the
LPS-induced inﬂammatory and/or promoting fetal maturation via
increased Ptgs2 expression and decreased 15-Hpgd expression in the
utero-placental tissues. Collectively, these data suggest that lipoxins
warrant further investigation as potential novel therapeutic options in
the treatment of PTL, which may be useful in protecting the fetus from
the adverse effects of infection-induced preterm birth.
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